Endogenous IL-33 has no effect on the progression of fibrosis during experimental steatohepatitis - Archive ouverte HAL Access content directly
Journal Articles Oncotarget Year : 2017

Endogenous IL-33 has no effect on the progression of fibrosis during experimental steatohepatitis

(1) , (2) , (2) , (2) , (3) , (4) , (5, 1) , (1) , (2) , (2)
1
2
3
4
5

Abstract

Interleukin (IL)-33 has been recently reported to be strongly pro-fibrogenic in various models of liver disease. Our aim was to study the role of endogenous IL-33 in a diet-induced model of steatohepatitis. IL-33 deficient mice and wild type (WT) littermates received a high-fat diet (HFD), or a standard diet for 12 weeks. The HFD-induced steatohepatitis was associated with an upregulation of IL-33 transcripts and protein. An insulin tolerance test revealed lower systemic insulin sensitivity in IL33-/-HFD mice than in WT-HFD mice. Nevertheless, IL-33 deficiency did not affect the severity of liver inflammation by histological and transcriptomic analyses, nor the quantity of liver fibrosis. Livers from HFD mice had more myeloid populations, markedly fewer NKT cells and higher proportion of ST2+ Treg cells and ST2+ type 2 innate lymphoid cells (ILC2), all unaffected by IL-33 deficiency. In conclusion, deficiency of endogenous IL-33 does not affect the evolution of experimental diet-induced steatohepatitis towards liver fibrosis.
Fichier principal
Vignette du fichier
Endogenous IL-33 has no effect.pdf (12.14 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Loading...

Dates and versions

hal-01578584 , version 1 (03-05-2018)

Identifiers

Cite

Philippe Vasseur, Sarah Dion, Aveline Filliol, Valentine Genet, Catherine Lucas-Clerc, et al.. Endogenous IL-33 has no effect on the progression of fibrosis during experimental steatohepatitis. Oncotarget, 2017, 8 (30), pp.48563--48574. ⟨10.18632/oncotarget.18335⟩. ⟨hal-01578584⟩
73 View
72 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More